- Home
- MASK vs FGEN Comparison
MASK vs FGEN Comparison
Compare MASK & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASK
- FGEN
- Stock Information
- Founded
- MASK 2017
- FGEN 1993
- Country
- MASK China
- FGEN United States
- Employees
- MASK N/A
- FGEN N/A
- Industry
- MASK
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MASK
- FGEN Health Care
- Exchange
- MASK NYSE
- FGEN Nasdaq
- Market Cap
- MASK 31.7M
- FGEN 34.5M
- IPO Year
- MASK 2025
- FGEN 2014
- Fundamental
- Price
- MASK $2.68
- FGEN $0.41
- Analyst Decision
- MASK
- FGEN Strong Buy
- Analyst Count
- MASK 0
- FGEN 1
- Target Price
- MASK N/A
- FGEN $10.00
- AVG Volume (30 Days)
- MASK 28.0K
- FGEN 8.1M
- Earning Date
- MASK 01-01-0001
- FGEN 05-05-2025
- Dividend Yield
- MASK N/A
- FGEN N/A
- EPS Growth
- MASK 55.43
- FGEN N/A
- EPS
- MASK 0.15
- FGEN N/A
- Revenue
- MASK $4,561,963.00
- FGEN $180,015,000.00
- Revenue This Year
- MASK N/A
- FGEN $22.77
- Revenue Next Year
- MASK N/A
- FGEN N/A
- P/E Ratio
- MASK $18.41
- FGEN N/A
- Revenue Growth
- MASK 172.95
- FGEN 16.15
- 52 Week Low
- MASK $2.50
- FGEN $0.18
- 52 Week High
- MASK $3.99
- FGEN $2.80
- Technical
- Relative Strength Index (RSI)
- MASK N/A
- FGEN 44.32
- Support Level
- MASK N/A
- FGEN $0.36
- Resistance Level
- MASK N/A
- FGEN $0.41
- Average True Range (ATR)
- MASK 0.00
- FGEN 0.07
- MACD
- MASK 0.00
- FGEN -0.01
- Stochastic Oscillator
- MASK 0.00
- FGEN 14.54
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business ("B2B") information technology ("IT") business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.